IMPORTANT DISCLAIMER: Blank Capital Research ("BCR") is a technology platform, not a registered investment advisor or broker-dealer. The algorithmically generated signals, scores, and rankings provided on this site ("God Mode" Signals) are for informational and research purposes only and do not constitute financial advice, investment recommendations, or an offer to sell or solicit an offer to buy any securities.
HYPOTHETICAL PERFORMANCE RESULTS: The "timing scores" and "regime signals" displayed are based on quantitative models. Hypothetical or simulated performance results have certain inherent limitations. Unlike an actual performance record, simulated results do not represent actual trading. Also, since the trades have not actually been executed, the results may have under-or-over compensated for the impact, if any, of certain market factors, such as lack of liquidity.
RISK OF LOSS: Trading in financial markets involves a high degree of risk and may result in the loss of your entire investment. Data provided by third-party sources (Intrinio, Snowflake) is believed to be reliable but is not guaranteed for accuracy or completeness. Past performance is not indicative of future results.
© 2026 Blank Capital Research. All rights reserved. System Version: Aegis V8 (God Mode).
Verdict
Quantitative factor alignment verified for current market regime.
Quant Score
Rank
#4304
Positioning
Market Dominance
Services
Computer Software
$423M
Robert Musslewhite
Definitive Healthcare Corp. provides healthcare commercial intelligence in the United States. The company's platform offers 16 intelligence modules that cover functional areas such as sales, marketing, clinical research and product development, strategy, talent acquisition, and physician network management. It serves biopharmaceutical and medical device companies, healthcare information technology companies, and healthcare providers.
Headcount
970
HQ Base
Pending Verification
Get full access to institutional-quality research tools with Blank Capital Pro.
Upgrade to ProStarting at $19.99/mo
Get full access to institutional-quality research tools with Blank Capital Pro.
Upgrade to ProStarting at $19.99/mo
Get full access to institutional-quality research tools with Blank Capital Pro.
Upgrade to ProStarting at $19.99/mo
Get full access to institutional-quality research tools with Blank Capital Pro.
Upgrade to ProStarting at $19.99/mo
Get full access to institutional-quality research tools with Blank Capital Pro.
Upgrade to ProStarting at $19.99/mo
X-AXIS: EV/EBITDA (LOWER = CHEAPER) | Y-AXIS: ROE (HIGHER = ELITE) | RED CIRCLE = DH ANALYSIS TARGET
| Stock | Rating | Score▼ | Quality | Value | Momentum | P/E | EV/EBITDA | ROE | ROA | Gross Mgn | Op Mgn | Net Mgn | Rev Growth | Div Yield | D/E | Mkt Cap | AUDIT |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
$YALA Yalla Group Ltd | 75 | 89 | 99 | 80 | - | - | - | - | - | - | - | - | - | - | $0 | VS | |
$GRVY GRAVITY Co., Ltd. | 75 | 82 | 96 | 71 | - | - | - | - | - | - | - | - | - | - | $0 | VS | |
$ISSC INNOVATIVE SOLUTIONS & SUPPORT INC | 73 | 81 | 88 | 94 | 25.0x | 14.1x | 17.1% | 10.3% | 35.5% | 14.6% | 10.1% | 105.2% | 0.0% | 41.0x | $244M | VS | |
$AER AerCap Holdings N.V. | 72 | 60 | 87 | 84 | - | - | - | - | - | - | - | - | - | - | $0 | VS | |
$HCSG HEALTHCARE SERVICES GROUP INC | 72 | 74 | 88 | 88 | 7.1x | 6.1x | 28.9% | 20.8% | 20.8% | 9.9% | 9.3% | 8.5% | 0.0% | 1.0x | $1.2B | VS | |
$LQDT LIQUIDITY SERVICES INC | 72 | 90 | 88 | 68 | 24.9x | 14.3x | 14.1% | 8.3% | 45.7% | 8.5% | 6.2% | 28.1% | 0.0% | 0.0x | $736M | VS | |
$TRTNpA Triton International Ltd | 71 | 70 | 89 | 70 | - | 1.7x | 0.0% | - | 97.4% | 58.0% | 37.4% | - | 8.8% | 264.0x | $2.5B | VS | |
$EDU New Oriental Education & Technology Group Inc. | 71 | 83 | 52 | 77 | - | - | - | - | - | - | - | - | - | - | $0 | VS | |
$NTES NetEase, Inc. | 71 | 88 | 93 | 68 | - | - | - | - | - | - | - | - | - | - | $0 | VS | |
$UTI UNIVERSAL TECHNICAL INSTITUTE INC | 70 | 86 | 86 | 72 | 43.2x | 16.0x | 15.3% | 5.8% | 100.0% | 6.9% | 5.2% | 15.1% | 0.0% | 24.0x | $1.8B | VS | |
$DH Definitive Healthcare Corp. | 33 | 38 | 46 | 13 | - | 100.5x | -95.0% | -49.0% | 76.4% | -173.2% | -151.6% | -5.8% | 0.0% | 94.0x | $423M | ||
| SECTOR BENCH | - | - | - | - | - | 23.7x | 11.7x | 5.7% | 2.4% | 64.6% | 4.5% | 2.8% | 8.6% | 0.0% | 0.3x | - | REF |
Definitive Healthcare Corp. (DH) receives a "Avoid" rating with a composite score of 33.0/100. It ranks #4304 out of 7,333 stocks in our coverage universe and carries a 1-star rating. Ratings are driven by a 6-factor quantitative model measuring quality, value, momentum, investment, stability, and short interest.
Sign in to join the discussion.
Lagging peers — losers tend to keep underperforming
Fair valuation relative to peers
Average quality profile
Average volatility — neutral timing signal
Aggressive spending — empire-building risk, dilutive growth
Below-average composite — caution warranted
Get full access to institutional-quality research tools with Blank Capital Pro.
Upgrade to ProStarting at $19.99/mo
Relative valuation derived from Services sector benchmarks. Model weights: EV/EBITDA (40%), P/B (35%), P/S (25%). Re-calculated daily.
No analyst ratings for DH.
View All Ratings| Factor | Global | Sector | Tilt |
|---|---|---|---|
| PROFITABILITY | 38 | 31 | +7ALPHA |
| MOMENTUM | 13 | 8 | +5NEUTRAL |
| VALUATION | 46 | 46 | 0NEUTRAL |
| INVESTMENT | 33 | 46 | -13DRAG |
| STABILITY | 42 | 40 | +2NEUTRAL |
| SHORT INT | 22 | 7 | +15ALPHA |
Global = full universe. Sector = relative to industry peers. Positive tilt indicates idiosyncratic strength.
ROIC -11.7% vs WACC 5.4% (spread -17.2%)
GM 76% vs sector 65%, OM -173% vs sector 5%
Capital turnover 1.02x, R&D intensity 13.8%
Rev growth -6%, 5yr history
Interest coverage -2.9x, Net debt/EBITDA 151.1x
Composite assessment of profitability, capital efficiency, and financial strength. Top-tier entities demonstrate sustainable cash flow generation and elite competitive moats.
Profit generated per dollar of shareholder equity
Efficiency of asset utilization
Pricing power and cost efficiency
Core business profitability
Bottom-line profitability
The Quality factor evaluates the persistence and magnitude of realized cash flows. Companies with scores >70 exhibit superior pricing power and structural financial resilience through diverse economic regimes.
Our uncertainty rating tracks the predictability of future cash flows and potential for permanent capital loss. Moderate visibility with standard industry cyclicality.
We rate Definitive Healthcare Corp. (DH) as Avoid with a composite score of 33.0/100 at a current price of $1.41. The stock falls in the bottom quintile, and the multi-factor weakness suggests a high probability of continued underperformance.
Definitive Healthcare Corp. holds a top-quartile position (#0 of 50) within the Services sector, based on our composite quantitative scoring across quality, value, momentum, and stability factors. The composite score of 33.0/100 places it at rank #4304 in our full universe.
No Moat
High
Poor
Fair Value
Gross margins of 76% signal strong pricing power.
Stable competitive position in a defensive sector.
Weak momentum suggests persistent institutional selling pressure.
Vulnerability to macroeconomic shocks and interest rate volatility.
Definitive Healthcare Corp. represents a avoid based on multi-factor quantitative performance.
Our quantitative model flags Definitive Healthcare Corp. with an Avoid rating, assigning a composite score of 33.0/100 and 1 out of 5 stars. Ranked #4304 of 7,333 stocks, DH falls in the bottom tier across key factors. Historically, stocks with this profile have faced elevated risk of underperformance and capital loss.
DH's quality score of 38/100 is below average, suggesting challenges with profitability or capital efficiency. The company reports a return on equity of -95.0% (sector avg: 5.7%), gross margins of 76.4% (sector avg: 64.6%), net margins of -151.6% (sector avg: 2.8%). Investors should examine whether management is actively addressing these weaknesses or if they reflect structural industry headwinds.
With a value score of 46/100, DH appears somewhat expensive relative to its fundamentals. Key valuation metrics include an EV/EBITDA of 100.51x, a P/B ratio of 0.40x. Investors paying a premium here are likely betting on above-average growth or margin expansion to justify current prices.
Definitive Healthcare Corp.'s investment score of 33/100 suggests limited reinvestment activity. Key growth metrics include revenue growth of -5.8% vs. a sector average of 8.6% and a return on assets of -49.0% (sector: 2.4%). While this can be positive for mature, cash-generative businesses returning capital to shareholders, it may also signal a lack of growth opportunities or management conservatism.
Definitive Healthcare Corp. is experiencing notably weak momentum with a score of just 13/100. The stock has underperformed its peers and is trending below major moving averages. Revenue growth stands at -5.8% year-over-year, while a beta of 0.87 reflects its sensitivity to broader market moves. While deep momentum weakness can occasionally present value opportunities, it often reflects deteriorating fundamentals or structural headwinds that may persist.
DH's stability score of 42/100 signals elevated volatility and/or leverage concerns. Key stability metrics include a beta of 0.87 and a debt-to-equity ratio of 94.00x (sector avg: 0.3x). Investors should be prepared for wider-than-average price swings and consider position sizing accordingly to manage portfolio risk.
Definitive Healthcare Corp.'s short interest score of 22/100 reveals significant bearish positioning, suggesting institutional investors are actively betting against the stock. Specific risk factors include elevated leverage (D/E: 94.00x), small-cap liquidity risk. At $423M (small-cap), DH carries meaningful risk and is best suited for investors with high risk tolerance who have thoroughly evaluated the bear thesis.
Definitive Healthcare Corp. is a small-cap company in the Services sector, ranked #0 of 50 in its sector (100th percentile) and #4304 of 7,333 overall (41st percentile). Key comparisons include ROE of -95.0% trailing the 5.7% sector median and operating margins of -173.2% below the 4.5% sector average. This top-quartile standing reflects exceptional competitive strength relative to Services peers.
While DH currently exhibits a AVOID profile, superior opportunities exist within the SERVICES sector. Our model identifies several "Strong Buy" candidates with higher quality scores and more attractive valuations among direct industry competitors.
View Top Services Alpha →Quant Factor Profile
Upgrade catalyst
Improvement in Momentum (13) would have the largest impact on the composite score.
EV/EBITDA 757% ABOVE SECTOR MEDIAN
ROE 1754% BELOW SECTOR MEDIAN
Gross Margin 18% ABOVE SECTOR MEDIAN (FAVORABLE)
Above 50MA
37.18%
Net New Highs
+51081
To the annoyance of some shareholders, Definitive Healthcare Corp. ( NASDAQ:DH ) shares are down a considerable 26% in...
FRAMINGHAM, Mass., Jan. 29, 2026 (GLOBE NEWSWIRE) -- Definitive Healthcare Corp. (“Definitive Healthcare”) (Nasdaq: DH), an industry leader in healthcare market data and analytics, today announced that it will report financial results for its fourth quarter and full year ended December 31, 2025, on Thursday, February 26, 2026 after market close. The company will host a conference call and webcast at 5:00 PM (ET) / 2:00 PM (PT) to discuss the company’s financial results. A live audio webcast of t
FRAMINGHAM, Mass., Jan. 07, 2026 (GLOBE NEWSWIRE) -- Definitive Healthcare (Nasdaq: DH), an industry leader in healthcare market data and analytics, today announced that its Chief Financial Officer, Casey Heller, will present at the 28th Annual Needham Growth Conference. The Definitive Healthcare presentation is scheduled for Wednesday, January 14, 2026, at 9:30 a.m. Eastern Time. A live webcast of the presentation will be available on the Events page of the Definitive Healthcare investor relati
DH vs. PRVA: Which Stock Is the Better Value Option?
Law Offices of Howard G. Smith is investigating Definitive Healthcare Corp. (DH) for possible violations of federal securities laws after the company disclosed a $363.6 million goodwill impairment and reduced its fiscal year 2024 guidance, causing a significant drop in its stock price.